Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.

Summary

This study aims to assess trough, TREM-1 levels and efficacy of IFX and ADA in IBD patients.

Timeline

Start

2022-01-01

Primary completion

2023-03-30

Completion

2023-04-01

Publications

• Background Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019 Apr-Jun;12(2):113-122. doi: 10.25122/jml-2018-0075.
• Background Fluxa, D. and M.T. Abreu, Therapeutic targets in inflammatory bowel disease. Revista Médica Clínica Las Condes, 2019. 30(4): p. 315-322.
• Background Shivaji UN, Sharratt CL, Thomas T, Smith SCL, Iacucci M, Moran GW, Ghosh S, Bhala N. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Mar;49(6):664-680. doi: 10.1111/apt.15097. Epub 2019 Feb 8.
• Kamal ME, Werida RH, Radwan MA, Askar SR, Omran GA, El-Mohamdy MA, Hagag RS. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. Inflammopharmacology. 2024 Oct;32(5):3259-3269. doi: 10.1007/s10787-024-01508-w. Epub 2024 Jul 10.

Drugs

Indications